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Background: Transition from intravenous (IV) epoprostenol to IV treprostinil in patients with
pulmonary hypertension (PH) has traditionally been performed by gradually decreasing the
epoprostenol dose while increasing the treprostinil dose. Preliminary data suggest that this
transition can be performed more rapidly without the need for epoprostenol weaning. We con-
ducted a single center, prospective clinical trial to assess the safety, efficacy, and treatment
satisfaction of rapidly switching from epoprostenol to IV treprostinil.
Methods: This study included patients with PH who had rapidly transitioned from epoprostenol
to IV treprostinil. Data collected included clinical status, adverse events, PH symptoms, and
previously validated measures of quality of life and treatment satisfaction.
Results: Ten patients were enrolled in this study. Exercise capacity measured by mean 6-min
walk distance was maintained from baseline throughout follow-up. Severity of disease as as-
sessed by WHO functional class was maintained or improved for the majority of patients.
Adverse events were minimal during the transition, and all patients remained on IV treprostinil
throughout the follow-up period. A favorable impact on quality of life and treatment satisfac-
tion measures was observed by eight weeks following the transition from epoprostenol to IV
treprostinil. Specifically, time spent on drug preparation activities decreased by 39.5% with
treprostinil compared to epoprostenol.of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic Main Campus, 9500 Euclid Ave,
16 445 2610; fax: þ1 216 445 1878.
.A. Minai).
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Rapid switch from epoprostenol to treprostinil 459Conclusions: Rapidly switching from epoprostenol to IV treprostinil can be achieved without
safety concerns, with minimal patient monitoring and without the need for extended hospital-
ization, while favorably impacting on patients’ quality of life.
ª 2012 Published by Elsevier Ltd.Introduction
Treprostinil (Remodulin) is a tricyclic benzidine prostacy-
clin analog that is a potent vasodilator and inhibitor of
platelet aggregation.1e3 Treatment of pulmonary arterial
hypertension (PAH) patients with treprostinil has been
shown to improve exercise capacity, as measured by the 6-
min walk distance (6MWD) test, and to also improve World
Health Organization (WHO) and New York Heart Association
(NYHA) functional class and cardiopulmonary
hemodynamics.4e7 In addition, data suggest that trepros-
tinil improves long-term survival in patients with PAH.1
The pharmacologic characteristics of treprostinil,
including a longer plasma elimination half-life than epo-
prostenol (4.5 h versus 2.7 min) and stability at room
temperature, allow for a simplified treatment regimen.8e10
Treprostinil is stable in Water for Injection, USP; sterile
saline, and Sterile Diluent for Flolan [(glycine, sodium
chloride buffer; pH 10.5) GlaxoSmithKline, Research
Triangle Park, NC, USA], at room temperature allowing
patients longer drug preparation and administration
intervals.10,11
Treprostinil was initially approved for subcutaneous (SC)
administration. Subsequently, intravenous (IV) administra-
tion was approved based upon bioequivalence between the
IV and SC routes of administration and has also demon-
strated efficacy in improving PAH symptoms.6,7,12,13
The safety and efficacy of transitioning patients from IV
epoprostenol to IV or SC treprostinil have been assessed in
several studies and treprostinil has also been demonstrated
to reduce the rate of clinical deterioration in patients
requiring transition from epoprostenol.7,12,14e16 Tradition-
ally, the transition from epoprostenol to IV treprostinil has
been conducted slowly, gradually lowering the epoproste-
nol dose while introducing treprostinil simultaneously over
the course of one to several days. However, Sitbon et al.
published the results of a study conducted in Europe that
evaluated the rapid 1:1 transition from epoprostenol to IV
treprostinil (without the need for concomitant infusion of
both therapies) in 12 patients with PAH classified as WHO
functional class I or II.12 The treprostinil dose was further
adjusted throughout the 12-week study to optimize the
dose for symptomatic benefit. Rapid transition to trepros-
tinil was achieved with no serious adverse events (SAEs) and
baseline clinical status was maintained at the end of the 12-
week study. Although all patients reported fewer
prostacyclin-related side effects using treprostinil versus
epoprostenol and all chose to remain on treprostinil after
study completion, formal assessments of treatment satis-
faction and quality of life (QOL) were not collected or
reported.
The goal of PH treatment is to lengthen survival time, to
ameliorate symptoms of PH and to improve quality of life.New therapies in PH have given clinicians and patients an
unprecedented array of treatment choices. There has been
little study of the effect changes in therapy have on
treatment satisfaction and health related quality of life
(HRQOL), despite their importance to patients. Here we
describe the results from a prospective study conducted to
confirm the safety and efficacy of rapidly transitioning PH
patients (WHO functional Class II or III) from IV epoproste-
nol to IV treprostinil, while also evaluating the impact of
the transition on overall treatment satisfaction and quality
of life. Additionally, the time spent on activities associated
with managing IV treprostinil therapy compared to that
with IV epoprostenol was captured. To our knowledge this is
the first study to compare treatment satisfaction in PH
patients before and after a therapy change.
Materials and methods
The study was a single-center, 8-week, open-label,
prospective study in adult subjects with pulmonary hyper-
tension enrolled at The Cleveland Clinic (ClinicalTrials.gov
Identifier: NCT00848939). The Cleveland Clinic Institu-
tional Review Board approved the protocol and all patients
provided written informed consent prior to entry into the
study.
The objectives of this study were to evaluate the safety
and efficacy of rapidly switching stable PH patients on IV
epoprostenol therapy to IV treprostinil. Additionally, the
impact of the change in therapy on HRQOL and treatment
satisfaction was assessed.
Eligible patients were enrolled over a five month period
and were between 18 and 70 years of age with stable WHO
functional class status II or III idiopathic pulmonary arte-
rial hypertension (IPAH), familial pulmonary arterial
hypertension (FPAH), associated pulmonary arterial
hypertension (APAH). The protocol was subsequently
amended to permit eligibility of patients with pulmonary
hypertension due to chronic thromboembolic pulmonary
hypertension (CTEPH). Additionally, all patients were
hemodynamically stable with no signs or symptoms of
disease progression, receiving continuous IV epoprostenol
therapy for at least three months, including a stable dose
for 30 days prior to enrollment, and had a baseline 6MWD
greater than 150 m.
The study consisted of a Screening period, a Baseline
visit (performed immediately prior to the switch to tre-
prostinil), and 8-week follow-up period after the transition,
during which subjects returned to the clinic at weeks 4 and
8. During the Screening period prior to transition, subjects
completed a 7-day diary documenting time spent on drug
administration activities with epoprostenol. Drug adminis-
tration diaries were repeated during week 7 on IV
treprostinil.
Table 1 Patient demographics and baseline
characteristics.
Parameter Patients (N Z 10)
Mean age (range), y 45.7 (25e68)
Female, n (%) 8 (80)




WHO functional class at
time of transition, n (%)
II 6 (60)
III 4 (40)
Years since PAH diagnosis,
mean (range)
3.7 (0.5e9.7)
Mean epoprostenol dose (range),
ng/kg/min
27.2 (15e58)
Concomitant PDE5I and/or ERA
medication, n (%)
4 (40)
Mean baseline 6MWD (range), m 447.7 (195e663)
Mean Borg symptom score (range) 2.55 (0e7)
CTD, PAH associated with connective tissue disease; CTEPH,
chronic thromboembolic pulmonary hypertension; IPAH, idio-
pathic PAH; 6MWD, 6-min walk distance; PAH, pulmonary arte-
rial hypertension; WHO, World Health Organization; PDE51,
phosphodiesterase 5 inhibitor; ERA, endothelin receptor
antagonist.
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epoprostenol therapy was terminated and treprostinil
therapy was started by directly switching the medication
reservoir of the CADD-Legacy infusion pump (Smiths
Medical MD, Inc, St Paul, MN). IV treprostinil was diluted to
the same concentration as the patient’s current dilution of
epoprostenol. The infusion rate remained the same for
approximately 30 min following the switch to clear any
remaining epoprostenol solution from the lumen of the
central venous catheter. After approximately 30 min, the
infusion rate was increased to provide a treprostinil dose
that was 20% higher on a ng/kg/min basis. Treprostinil
dosing was titrated throughout the eight week follow-up
period to optimize the dose for symptomatic benefit
based on clinical signs/symptoms, exercise capacity and
tolerability.
All patients were discharged from the hospital within
24e48 h following the initiation of treprostinil after the
dose had been stabilized (based on clinical symptoms of PH
and tolerability) and the patient had demonstrated the
ability to self-administer IV treprostinil.
Safety and efficacy (i.e., the maintenance of baseline
status) were assessed by physical examination, clinical
laboratory and vital sign assessments, adverse events, WHO
functional classification, PH symptoms (fatigue, dyspnea,
edema, dizziness, syncope, and chest pain), and 6MWD test
with Borg dyspnea score. Changes between Baseline and at
8 weeks were assessed using the Wilcoxon signed rank test.
A 2-sided p value of <0.05 was considered statistically
significant. No imputation was used for missing values.
Since subjects entered the study and transitioned from an
existing prostacyclin therapy, known prostacyclin class side
effects (headache, jaw pain, flushing, diarrhea, rash, foot
pain, nausea, and vomiting) were captured using a prosta-
cyclin side effect questionnaire administered at Baseline,
and repeated on day 2 and weeks 4 and 8 following the
transition.
Quality of life and treatment satisfaction was assessed
using four different patient-reported outcomemeasures: (1)
the Treatment Satisfaction Questionnaire for Medication
(TSQM), a validated generic measure of treatment satisfac-
tion consisting of 14 Likert-response items comprising four
domains: Effectiveness, Side Effects, Convenience, and
Global Satisfaction17; (2) the Cambridge Pulmonary Hyper-
tension Outcome Review (CAMPHOR), a validated PAH-
specific instrument consisting of 65 items used to assess
symptoms, functioning and QOL18; (3) a Patient Global
Impression of Change Questionnaire, which consists of three
items that ask the patient to rate changes (much better,
somewhat better, about the same, somewhat worse, much
worse) in their symptoms of PH, the amount of time spent on
activities associated with preparing and administering PH
therapy, and their satisfaction with their PH therapy since
transitioning from epoprostenol to IV treprostinil; and (4)
a Drug Administration Activities Diary, used by patients to
record in detail the amount of time (in minutes) spent on
specifically-defined drug preparation/administration activi-
ties, was completed over a 7-day period during the Screening
period while on epoprostenol and repeated over week 7
following transition to treprostinil.
Changes in mean TSQM and CAMPHOR scores between
Baseline and 8 weeks were assessed using the Wilcoxonsigned rank test. A 2-sided p value of <0.05 was considered
statistically significant. No imputation was used for missing
values. Patient responses to the Patient Global Impression
of Change Questionnaire (administered at week 8 only) are
summarized as frequency distributions. Drug Administration
Activities Diary results are reported as average time per
week spent on drug administration activities before and
after transition of therapy.
Results
Baseline characteristics
Ten subjects transitioned to IV treprostinil and successfully
completed study assessments. Eighty percent of the
subjects were female, and the mean age was 45.7 years
(range, 25e68 years; Table 1). IPAH was the most common
etiology (70%). All subjects were WHO functional class II or
III at Baseline on epoprostenol therapy.
Safety and tolerability
All subjects successfully completed the rapid switch tran-
sition and none exhibited acute or delayed clinical deteri-
oration. An increase in the severity of headache occurred in
two subjects (one severe), flushing in three subjects (two
severe), rash in one subject (severe), and foot pain in one
subject (mild) during the first 24 h following the transition
from epoprostenol to treprostinil. Comparing recorded side
effects at week 8 to Baseline, an increase in the severity of
Figure 1 Six-minute walk distance at Baseline and post-
transition for all 10 individual patients showing patient PH
etiology (IPAH, idiopathic pulmonary hypertension, ACVD or
CTD, CTEPH, chronic thromboembolic pulmonary hyperten-
sion) and WHO functional class (II or III) at Baseline. *Denotes
subject with an out of window visit.
Rapid switch from epoprostenol to treprostinil 461headache was reported in one subject (mild to moderate),
diarrhea in two subjects (both none to mild) and foot pain
in two subjects (none to mild and none to moderate). The
severity of all other side effects was unchanged or
improved at week 8. Overall, a reduction in the frequency
and intensity of prostacyclin side effects were documented
with treprostinil compared with epoprostenol (Table 2),
and no subjects were transitioned back to epoprostenol at
the end of the 8-week study. Two serious adverse events
were reported during the study (gastroenteritis and enter-
itis), but judged not attributable to treprostinil. No deaths
occurred during the study period. Mean treprostinil dose at
time of final observation was 49  21 ng/kg/min.
Changes in functional parameters
The mean change in 6MWD remained stable at 4 weeks
(n Z 9; 8.3  37.9 m; p Z NS) and 8 weeks (n Z 9;
2.2  34.8 m, p Z NS) relative to Baseline 6MWD on
epoprostenol and changes in individual patients were not
significant (Fig. 1). The mean Borg dyspnea score was 2.06
at Baseline and increased to 3.61 (n Z 9; p Z 0.008) at
week 8. At week 8, Baseline WHO functional class was
maintained in eight subjects, and one subject improved
from class II to class I.
One subject was excluded from the week 8 analysis
because their visit occurred more than two weeks outside
of the visit window and one subject did not have a week 4
visit performed. A summary of the changes in all functional
parameters is depicted in Table 3.
Patient centered outcomes
Patient centered outcomes are reported for all subjects. The
results from the TSQM showed statistically significant
improvements fromBaseline (on epoprostenol) toweek 8 (on
treprostinil) as indicated by an increase in the component
scores for Effectiveness (þ10.6  11.2; p Z 0.02), Side
Effects (þ13.1 11.6; pZ 0.02), Convenience (þ30.0 9.5;
pZ 0.002), and Global Satisfaction (þ7.9  8.6; pZ 0.02)
(Fig. 2). Ninety percent of patients had increasedTable 2 Summary of patient responses to prostacyclin side effe




N None Mild Moderate Severe Nb None
Headache 10 4 3 3 0 8 4
Jaw pain 10 1 4 4 1 8 3
Flushing 10 2 3 3 2 8 2
Diarrhea 10 2 2 6 0 8 2
Rash 10 6 2 2 0 8 7
Foot pain 10 6 0 3 1 8 7
Nauseaa 9 6 3 0 0 7 5
Vomitinga 9 8 1 0 0 7 7
Total event no
by severity
31 18 21 4 37
a One questionnaire did not have subject responses for nausea or v
b Two subjects did not have responses for the first 24 h.
c Includes the nominal Week 8 assessment which occurred out of thEffectiveness component scores, eighty percent had
increased Side Effect component scores, one-hundred
percent had increased Convenience component scores, and
seventy percent had increased Global Satisfaction scores
while receiving treprostinil versus epoprostenol.
According to the results of the CAMPHOR, overall patient
health status improved at week 8 (on treprostinil)
compared to Baseline (on epoprostenol) as indicated by
reduced mean component scores in Symptoms (2.0  3.7;
p Z 0.15) Quality of Life (4.2  3.9; p Z 0.02) and Total
Score (5.6  12.2; p Z 0.15) (Fig. 3). Sixty percent of
patients had improved (i.e., reduced) Symptom scores (one
remained the same), seventy percent had improved Quality
of Life scores (two remained the same) and eighty percent
had improved Total scores while on treprostinil compared
with epoprostenol. There was no change in the Activity
component score (þ0.6; p Z 0.84), consistent with main-
tenance of subject functional status.
The results from the Patient Global Impression of Change
questionnaire indicated that the majority of patients werects questionnaire.
patients reporting at
ostinil)
Number of patients reporting at
week 8 (treprostinil)
Mild Moderate Severe Nc None Mild Moderate Severe
2 1 1 10 6 2 2 0
1 3 1 10 5 5 0 0
3 1 2 10 6 3 1 0
2 4 0 10 2 6 2 0
0 1 1 10 8 2 0 0
1 1 0 10 4 3 2 1
2 0 0 9 8 1 0 0
0 0 0 9 9 0 0 0.
11 11 5 48 22 7 1
omiting.
e visit window.
Table 3 Summary of efficacy variables.
Variable Change from baseline at week 8 (N Z 9) p-Value
6MWD, m (mean  SD) 2.2  34.8 p Z 1.00
Borg score (mean  SD) 1.56  0.98 p Z 0.008
Variable Improved No Change Worsened p-Value
WHO class (% of subjects) 11% 89% 0% p Z 1.00
PAH signs/symptoms (% of subjects)
Fatigue 22% 67% 11% p Z 1.00
Dyspnea 22% 33% 44% p Z 0.53
Edema 22% 56% 22% p Z 1.00
Dizziness 11% 89% 0% p Z 1.00
Syncope 0% 100% 0% p Z 1.00
Chest pain 0% 89% 11% p Z 1.00
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much better, and spent much less time dealing with IV
treprostinil therapy compared with epoprostenol (Table 4).
Based on patients’ drug preparation/administration diaries
(n Z 10) they reported an average of 40% less time per
week on activities associated with drug administration with
IV treprostinil compared with IV epoprostenol (Fig. 4). Most
notably, subjects reported a decrease in time spent
preparing drug solution (such as mixing, preparing drug
cassette or drawing up into a syringe) from 106.6 min
a week with epoprostenol to 47.1 min (p Z 0.002) with
treprostinil.Discussion
Data obtained this study indicate that rapid transition from
epoprostenol to IV treprostinil had a favorable impact on all
patient measures of treatment satisfaction and quality of
life. Notably, transitions were performed without signifi-
cant clinical deterioration, measures of functional status
were maintained for the majority of patients, and no
patients reverted to epoprostenol during the 2-month study
treatment period. Our findings build upon evidence from
previous studies suggesting that rapid transition fromFigure 2 TSQM (Treatment Satisfaction Questionnaire for Medic
increase in satisfaction; *p < 0.05.epoprostenol to IV treprostinil can be achieved without
gradual down-titration of epoprostenol and up-titration of
treprostinil over several days or extended hospitalization
with monitoring, and results in greater convenience for
patients.
A concern with rapidly transitioning patients from epo-
prostenol to IV treprostinil is the risk of cardiovascular
collapse or severe AEs. The results of this study were
consistent with the findings of the 12-week, prospective,
open-label, rapid switch study conducted at two centers in
Europe, and with findings from a preliminary retrospective
chart review we conducted previously at five US PAH
centers of 24 patients who had transitioned from IV epo-
prostenol to IV treprostinil using “rapid switch”
methods.12,19 In contrast to the European rapid switch
study, in which the initial starting doses of IV treprostinil
were equivalent to those of epoprostenol at the time of
transition, the treprostinil doses during transition in this
study were 20% higher. The transition from epoprostenol to
IV treprostinil at a 1:1.20 dose on a ng/kg/min basis was
selected based upon the findings of a retrospective chart
review conducted to evaluate dosing strategies employed
at centers with experience successfully performing such
transitions. Initially, rapid transitions occurred at the 1:1
epoprostenol to treprostinil dose ratio and were titratedation) component scores (n Z 10). Increase in score denotes
Table 4 Summary of patient responses to patient
impression of change questionnaire.
Compared to your previous experience with Flolan, please
rate your satisfaction with intravenous Remodulin
therapy over the past two weeks:
Much more satisfied 8
More satisfied 2
About the same 0
Less satisfied 0
Much less satisfied 0




About the same 3
Somewhat worse 0
Much worse 0
Compared to your previous experience with Flolan, how




About the same 1
Somewhat more 0
Much more 0
Rapid switch from epoprostenol to treprostinil 463upward. Later transitions at these centers occurred at
treprostinil doses 20%e25% higher than epoprostenol with
minimal dose titrations. In the limited number of patients
who were transitioned to an IV treprostinil dose 50% higher
than the initial epoprostenol dose, considerable signs of
prostacyclin excess, headache, nausea, and vomiting, were
reported and several dose reductions were required during
the first hours following the transition.
Rapid transition in the current prospective study was well
tolerated. Adverse events experienced by patients in this
study were consistent with those reported during a study of
graduated transition from epoprostenol to IV treprostinil,Figure 3 CAMPHOR (Cambridge Pulmonary Hypertension Outco
denotes improved health status; *p < 0.05.wherein the epoprostenol dose was decreased as IV tre-
prostinil dose was increased over the course of 24e48 h7
At the end of the two-month study treatment period,
measures of functional status were maintained for the
majority of patients, and no patients reverted to epopros-
tenol. An increase in the mean Borg dyspnea score was
observedatweek 8 compared toBaseline (nZ9; 1.56 0.98;
p Z 0.008); however, five of the nine patients with an
increased Borg dyspnea score also showed a corresponding
increase in 6MWDand nopatients declined inWHO functional
class. Treprostinil was titrated throughout the eight-week
follow-up period to optimize the dose for symptomatic
benefit and achieve the maximum tolerated dose in terms of
adverse experiences while maximizing the improvement in
both clinical signs and symptoms and exercise capacity. The
mean treprostinil dose at time of final observation was
49  21 ng/kg/min compared to a Baseline mean epopros-
tenol dose of 27.2 ng/kg/min and the relative absence of
prostacyclin associated adverse events at week 8 suggests
that patients may not have reached their maximum dose at
the end of the eight week period. As a consequence, tre-
prostinil therapy may not have been fully optimized at the
end of the short follow-up period.
Although this study focused on the patient status and
outcomes of the rapid switch procedure itself, including the
two-month period immediately following the transition,
maintenance of exercise capacity and cardiopulmonary
hemodynamics at one year following transition from epo-
prostenol to IV treprostinil has been reported.20,21
Transitioning from epoprostenol to IV treprostinil has the
added potential to ease patient treatment burden by
enhancing convenience, decreasing complexity of treat-
ment, and improving tolerability. In our preliminary retro-
spective study, “decreased treatment complexity” was
documented in 14 of the 24 patients examined as the
reason for transitioning from epoprostenol to treprostinil,
with longer half-life/lowered risk of treatment interruption
and tolerability (severe leg pain, thrombocytopenia on
epoprostenol) documented in eight of the 24 patients.19 To
quantitatively assess such factors prospectively, we
administered reliable, validated instruments (TSQM and
CAMPHOR), further complemented by use of a Patient
Global Impression of Change Questionnaire andme Review) component scores (n Z 10). Reduction in score
Figure 4 Average time (in minutes) per week patients spent
on drug administration activities at Baseline (while patient was
receiving epoprostenol) and week 8 (while patient was
receiving treprostinil) (n Z 10).
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and treatment satisfaction measures was observed by eight
weeks following the transition. Statistically significant
improvement was achieved in multiple domains of the
TSQM including side effects, convenience and global satis-
faction component scores as well as in the CAMPHOR QOL
component. The treatment satisfaction and QOL changes
may have been related in part to the fact that patients
using treprostinil change medication every 48 h, rather
than every 24 h with epoprostenol; the patient diaries
showed that time spent on drug preparation activities
decreased by approximately 40% with treprostinil compared
with epoprostenol; extrapolated over a year patients in this
study had the potential to spend 68 h less on activities
related to drug administration with IV treprostinil than
epoprostenol. Patients in this study transitioned therapy
prior to the availability of Veletri, a more thermostable
formulation of epoprostenol; therefore, our results cannot
be extrapolated to patients transitioning from Veletri. The
main limitations of this study are the modest sample size
and relatively short duration of follow-up. Given the limited
population available for study (PAH patients on stable IV
epoprostenol therapy), ten patients represents a meaning-
ful, albeit, modest number of patients. The direction of the
effect observed was similar across multiple types of
instruments, consistent with a true effect. The likelihood of
all measures independently showing a similar effect by
chance alone would be low. In this study, a favorable
impact on quality of life and treatment satisfaction
measures was observed as early as eight weeks following
transition from epoprostenol to IV treprostinil; the dura-
bility of the improvements in patient satisfaction and
HRQOL beyond the initial two month period following the
switch is unknown. The long-term effects of changing
therapies on patient satisfaction and HRQOL in patients
with pulmonary hypertension merits further study.
Another limitation of this study is the potential for
selection bias. Patients who were not satisfied with their
current treatment (epoprostenol)may have beenmore likely
to enroll in our study, thereby increasing the likelihood
detecting a reported improvement with change in therapy.
We attempted to reduce such bias by enrolling only those
patients that were on stable continuous IV epoprostenol
therapy for at least threemonthswith no evidence of disease
progression, but we acknowledge the possibility of residualbias. Nonetheless, even in the presence of a selection bias,
our results remain valid among those patients who are not
satisfied with their current treatment, arguably the most
relevant population for transition.
Although treatment satisfaction with therapy has not
been well studied in PH, patient satisfaction with different
modes of drug delivery has been explored in other chronic
medical conditions. For example, an open-label prospec-
tive, cross-over, randomized trial comparing intraperito-
neal versus subcutaneous infusion of insulin in type 1
diabetics resulted in a measurable improvement in both
patient satisfaction and quality of life. In therapeutic areas
such as diabetes where multiple equally efficacious treat-
ment options exist, there is an increasing interest in
assessing the effect of different treatment modalities on
patient-centered outcomes.22,23
The concept of treatment satisfaction is likely to be highly
relevant in the treatment of PAH, for which there are now
currently multiple FDA-approved therapies available in the
United States. In the absence of head-to-head trials for
approved PAH therapies, decisions regarding which type of
therapy to choose is likely to be driven in part by patient
preferences. The model of shared-decision making, with
patient’s contributing to their own medical-decision making,
is an evolving paradigm that continues to mature. Additional
research, particularly in PAH, is needed to determine not only
“efficacy”, but the “effectiveness” of therapy under ‘real-
world’ conditions. The efficacy of any treatment must be
considered in the context under which that intervention is
administered, including the frequency of dose titration, need
for monitoring, concerns regarding drug stability, potential
for adverse effects, and ease of delivery. Logically, those
therapeutic modalities associated with greater treatment
satisfaction and convenience are more likely to be deemed
acceptable by patients (and possibly more effective as well).
In summary, our results suggest that changing from epo-
prostenol to IV treprostinil can occur as a rapid transition at
a 1:1.2 dose ratio on a ng/kg/min basis by direct exchange of
the CADD medication reservoir without extended hospitali-
zation or monitoring, with preserved functional class in
selected patients, and is associated with reduced time
required for drug administration related activities and has
the potential to improve patient satisfaction with treatment
and quality of life. Additional studies on the long-term
effects on patient satisfaction and HRQOL in patients with
pulmonary hypertension are warranted.Acknowledgments
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